Sponsored by:
P2023Development of 8 New No-Wash Immunoassay Kits for the Detection of VEGF, Amyloid Beta1-40, Amyloid Beta1-42, Insulin, Human IgG, EPO, HIV p24 & TNFalpha Using PerkinElmer AlphaLISA
Presenter Stephane Parent, PerkinElmer Biosignal, Canada
Additional Authors: Valérie Paquet, Anja Rodenbrock, Marie-Hélène Venne, and Véronique Brechler
ELISA is the most widely adopted method for detection and quantification of low analyte concentrations. This traditional technology offers good selectivity, sensitivity and assay versatility; however, it has certain disadvantages such as limited dynamic range and limited throughput. In addition, the numerous required wash-steps limit its ability to measure low affinity antibodies. The PerkinElmer AlphaLISA® platform does not face these limitations. It does not require any wash steps. Assay development is simple and fast and hands-on time as well as total assay time, are significantly reduced. These low variability assays are easy to miniaturize and automate enabling an efficient High-throughput Screening set-up.VEGF, Amyloid b1-40, Amyloid b1-42, Insulin, human IgG, EPO, HIV p24 and TNFa AlphaLISA assays were fully developed for detection and quantification of the analytes in cell culture supernatants and serum samples. Standard curves showing Lower Detection Limit (LDL) and dynamic range will be presented for each analyte as well as assay variability results. Excellent performance is demonstrated with large dynamic ranges, high sensitivities, high accuracy and precision. The overall results confirm the user-friendly AlphaLISA technology as a new generation of tools available for immunoassays. Optimized assays for the listed analytes were converted to kit form to improve the accessibility of AlphaLISA technology to more researchers.